FormFactor Inc. FormFactor Inc. Common Stock vs Smith & Nephew plc — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $141.38 (market cap $10.92B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: FormFactor Inc. FormFactor Inc. Common Stock and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while FormFactor Inc. FormFactor Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 0 Days and Smith & Nephew plc for 120 Days on average.
| FORM | SNN | |
|---|---|---|
Market Cap | $10.92B | $11.31B |
Volume | 1,056,924 | 1,050,005 |
Sector | Technology | Health |
52-Week High | $159.93 | $37.17 |
52-Week Low | $38.14 | $26.42 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $10.61B | $14.35B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →